Acrivon Therapeutics (ACRV) stock: insider trades, news & valuation
Strong buyingShare price and insider trades
Acrivon Therapeutics insider trading at a glance (Oct 9, 2026): in the past 12 months, 3 insiders bought $115K and 7 sold $40K of ACRV stock on the open market, including a cluster buy that began Jan 13, 2026.
Get emailed when insiders cluster-buy stocks like ACRV
Free alerts the day a new cluster buy is filed, plus the Monday report of the week's biggest insider trades.
Free · unsubscribe anytime · not investment advice · see a sample issue
ACRV insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | — | 0 | $585 | 1 |
| Q3 2026 | — | 0 | $40K | 9 |
| Q2 2026 | — | 0 | — | 0 |
| Q1 2026 | $115K | 3 | — | 0 |
Valuation, profit and volume
Summary
Over the past 12 months, 3 Acrivon Therapeutics, Inc. insiders reported open-market purchases totaling $115K, while 7 insiders reported sales totaling $40K. The most recent cluster buy began on Jan 13, 2026, when 3 insiders bought a combined $115K. 0 of 10 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.
ACRV earnings: how the stock reacted
Each quarterly results release (SEC 8-K Item 2.02), the trend before it, insider trades in the 30 days before, and the 2-day market reaction. “E” marks releases on the chart above.
| Release | 15 days before | Insiders, 30 days before | Reaction (2 days) | Next 30 days |
|---|---|---|---|---|
| Aug 12, 2026 | +10.9% | Sold $3K | +6.9%S&P +0.9% | +8.1% |
| May 13, 2026 | +0.5% | None | +1.6%S&P +1.4% | -22.9% |
| Mar 19, 2026 | -1.8% | None | +1.2%S&P -1.7% | +7.2% |
| Jan 8, 2026 | +27.2% | None | -40.7%S&P +0.7% | -4.6% |
| Nov 13, 2025 | +15.2% | None | -1.8%S&P -1.7% | +12.9% |
| Aug 13, 2025 | -12.6% | None | +11.2%S&P +0.4% | +9.4% |
| May 14, 2025 | -27.1% | None | -2.7%S&P +0.6% | +9.1% |
| Mar 25, 2025 | +1.3% | None | -53.5%S&P -1.0% | -37.2% |
Most companies bar insiders from trading in the weeks before results, so pre-earnings purchases are rare and often made by directors or under pre-set plans. Past reactions don't predict future ones.
Insider transactions
Open-market purchases and sales.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Oct 7SEC | Mary MillerGeneral Counsel | Sell | 29481,715 held (−0%) | $1.99 | $585 | -4.0% | — |
| Aug 27SEC | Peter Blume-jensenCEO, President | Sell | 14,0362,230,052 held (−1%) | $2.21 | $31K | -13.6% | — |
| Aug 20SEC | Kristina MassonEvp - Business Operations | Sell | 1,2292,244,088 held (−0%) | $2.01 | $2K | -5.0% | — |
| Aug 20SEC | Eric DevroeCOO | Sell | 604146,349 held (−0%) | $2.01 | $1K | -5.0% | — |
| Aug 20SEC | Kristina MassonEvp - Business Operations | Sell | 484385,859 held (−0%) | $2.01 | $973 | -5.0% | — |
| Aug 20SEC | Erick GamelinChief Development Officer | Sell | 40052,592 held (−1%) | $2.01 | $804 | -5.0% | — |
| Aug 20SEC | Mary MillerGeneral Counsel | Sell | 18582,009 held (−0%) | $2.01 | $372 | -5.0% | — |
| Aug 20SEC | Katharine PetersonChief Accounting Officer | Sell | 10118,033 held (−1%) | $2.01 | $203 | -5.0% | — |
| Aug 6SEC | Adam D. LevyCFO | Sell | 1,14266,008 held (−2%) | $1.57 | $2K | +21.7% | — |
| Jul 23SEC | Mary MillerGeneral Counsel | Sell | 57382,194 held (−1%) | $1.76 | $1K | +8.5% | — |
| Jan 16SEC | Peter Blume-jensenCEO, President | Buy | 49,0002,095,771 held (+2%) | $1.68 | $82K | +13.7% | — |
| Jan 16SEC | Adam D. LevyCFO | Buy | 8,83220,983 held (+73%) | $1.70 | $15K | +12.4% | — |
| Jan 15SEC | Eric DevroeCOO | Buy | 10,00075,308 held (+15%) | $1.72 | $17K | +11.0% | — |
Insiders at Acrivon Therapeutics, Inc.
| Insider | Bought | Sold | Last filing | Score |
|---|---|---|---|---|
| Peter Blume-jensenCEO, President | $82K | $31K | Aug 27, 2026 | — |
| Eric DevroeCOO | $17K | $1K | Aug 20, 2026 | — |
| Adam D. LevyCFO | $15K | $2K | Aug 6, 2026 | — |
| Kristina MassonEvp - Business Operations | — | $3K | Aug 20, 2026 | — |
| Mary MillerGeneral Counsel | — | $2K | Oct 7, 2026 | — |
| Erick GamelinChief Development Officer | — | $804 | Aug 20, 2026 | — |
| Katharine PetersonChief Accounting Officer | — | $203 | Aug 20, 2026 | — |
ACRV stock: common questions
Are Acrivon Therapeutics, Inc. insiders buying ACRV stock?
In the past 12 months, 3 insiders reported open-market purchases of ACRV worth $115K. The latest was CEO, President Peter Blume-jensen bought $82K of ACRV at $1.68 — first open-market purchase in our records.
Are Acrivon Therapeutics, Inc. insiders selling ACRV stock?
7 insiders reported sales worth $40K over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.
What is ACRV's 52-week range?
Over the past year ACRV has traded between $1.29 and $3.01. It last closed at $1.91 on Oct 9, 2026.